Patents Assigned to Merck
  • Mono-, oligo-and polyalkylidenefluorenes and their use as charge transport materials
    Patent number: 6805922
    Abstract: Conjugated mono-, oligo- and polyalkylidenefluorenes are suitable for use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: October 19, 2004
    Assignee: Merck Patent GmbH
    Inventors: Martin Heeney, Steven Tierney, Mark Giles, Louise Diane Farrand, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Mono-, oligo- and poly-3-(1,1-difluoroalkyl)thiophenes and their use as charge transport materials
    Patent number: 6806374
    Abstract: Mono-, oligo- and polymers comprising one or more identical or different recurring units of formula I —[(Y)a—(D)b—(Z)c]—  I wherein D is a 3-(1,1-difluoroalkyl)thiophene group of formula II, wherein Y, Z, R1, R2, a, b and c have the meanings defined herein, are useful as semiconductors and charge transport materials.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 19, 2004
    Assignee: Merck Patent GmbH
    Inventors: Martin Heeney, Louise Farrand, Mark Giles, Marcus Thompson, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Liquid-crystalline medium
    Patent number: 6805923
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds having positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I in which R, A, L1, L2 and Y are as defined herein are suitable for use in liquid crystal displays such as MLC, TN or STN displays.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: October 19, 2004
    Assignee: Merck Patentgesellschaft Mit
    Inventors: Michael Heckmeier, Brigitte Schuler, Peer Kirsch, Eike Poetsch
  • 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
    Patent number: 6800647
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: in combination with a pharmaceutically acceptable carrier, said compound being comprised of about 1-50%, 1-20% or 1-10% of the polymorphic form which is designated Form V and the remainder of the compound being comprised of at least one polymorphic form selected from the group consisting of: Form I, Form II, Form III and Form IV.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: October 5, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Process for the synthesis of estrogen receptor modulators
    Patent number: 6800785
    Abstract: The present invention relates to processes for the synthesis of intermediates useful for the synthesis of estrogen receptor modulators. The process includes new methods for annelating 5-, 6- and 7-membered cycloalkenones onto an indanone.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: October 5, 2004
    Assignee: Merck & Co., Inc.
    Inventor: Dongfang Meng
  • Electro-optical liquid-crystal display
    Patent number: 6800338
    Abstract: To provide an electro-optical liquid-crystal displays with low addressing voltages and low to moderate multiplex ratios, in particular STN displays, organic alignment layers of low layer thickness are utilized.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: October 5, 2004
    Assignee: Merck Patentgesellschaft
    Inventors: Thomas Jacob, Juliane Suermann
  • Reactive thienothiophenes
    Patent number: 6800763
    Abstract: The invention relates to reactive thienothiophenes, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive thienothiophenes.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: October 5, 2004
    Assignee: Merck Patent Geselleshaft MIT Beschraenkter Haftung
    Inventors: Louise Farrand, Marcus Thompson, Mark Giles, Mark Goulding, Martin Heeney, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Connecting system for plastic columns
    Patent number: 6797174
    Abstract: The invention relates to a plastic cartridge system including a cartridge having a plastic-covered column, said column including a monolithic sorbent and at least one closing cap which is applied to the ends of the column. The cartridge also includes a connecting system having at least one divided supporting screw which is held in position by a closing cap or a spacer ring, and at least one end piece which can be screwed onto a supporting screw in order to connect an elution agent inlet and an elution agent outlet.
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: September 28, 2004
    Assignee: Merck Patent GmbH
    Inventors: Willi Neuroth, Günter Sättler, Klaus Kreher
  • Method for reducing the immunogenicity of antibody variable domains
    Patent number: 6797492
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 28, 2004
    Assignees: Merck & Co., Inc., United States of America
    Inventors: Bruce L. Daugherty, George E. Mark, III, Eduardo A. Padlan
  • Process for the scaleable purification of plasmid DNA
    Patent number: 6797476
    Abstract: The present invention relates to a nonchromatographic-based process for the isolation of clinical grade plasmid DNA from bacterial cells. The exemplified methods described herein outline a scaleable, economically favorable protocol for the purification of clinical grade plasmid DNA from E. coli which includes CTAB-based precipitation of DNA in combination with adsorption of impurities to calcium silicate.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: September 28, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Russel Jackson Lander, Michael Albert Winters, Francis Jeremiah Meacle
  • Alicyclic imidazoles as H3 agents
    Patent number: 6794405
    Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H3 receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: September 21, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Yajing Rong, Jack B. Jiang, Syed M. Ali
  • Fluoroalkylphosphate salt electrolytes
    Patent number: 6794083
    Abstract: The present invention relates to mixtures of fluoroalkylphosphate salts and polymers, methods of producing same, and their use in electrolytes, batteries, capacitors, supercapacitors and galvanic cells.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: September 21, 2004
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Michael Schmidt, Frank Ott, Michael Jungnitz, Nikolai Ignatyev, Andreas Kuehner
  • Tyrosine kinase inhibitors
    Patent number: 6794393
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Method for producing high-purity hydrochloric acid
    Patent number: 6793905
    Abstract: This invention relates to a novel method, which can be carried out according to industrial standards, for producing high-purity hydrochloric acid with a very low particle content, for use in the production of semiconductors.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck Patent GmbH
    Inventors: Werner Büttner, Martin Hostalek, Ching-Jung Kan, Chih-Peng Lu
  • Liquid crystalline medium and liquid crystal display
    Patent number: 6793985
    Abstract: Liquid crystalline media comprising a dielectrically positive component A, comprising compounds of formula I wherein the parameters have the meanings given herein, are suitable for use in liquid crystal displays, especially to active matrix displays and in particular IPS displays.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck Patent GmbH
    Inventors: Shinji Nakajima, Yasushi Sugiyama, Yukiomi Tanaka, Takanori Takeda, Hideo Ichinose
  • Fluorinated (dihydro)phenanthrene derivatives, and their use in liquid-crystalline media
    Patent number: 6793984
    Abstract: The invention relates to liquid-crystalline (dihydro)phenanthrene derivatives of the formula I in which R, G, A1, Z1, m, L1, L2, L3, L4, L5 and Y are as defined in claim 1, and to liquid-crystalline media comprising at least one (dihydro)phenanthrene derivative of the formula I, and to electro-optical displays containing a liquid-crystalline medium of this type.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: September 21, 2004
    Assignee: Merck Patent Beschraenkter Haftung
    Inventors: Matthias Bremer, Detlef Pauluth, Michael Heckmeier, Hans-Rolf Dübal, Barbara Hornung, Wolfgang Schmidt, Rainer Wingen
  • Liquid crystal medium
    Patent number: 6793983
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it comprises one or more compounds of the general formula I and at least one compound of the formula in which the substituents are as defined in claim 1.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: September 21, 2004
    Assignee: Merck Patent GmbH
    Inventors: Michael Heckmeier, Brigitte Schuler, Kazuaki Tarumi, Peer Kirsch, Volker Reiffenrath
  • Liquid-crystalline medium
    Patent number: 6790489
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of negative dielectric anisotropy which comprises at least one compound of the formula I in which R11, R12, A1, Z1, ring A and m are as defined in claim 1, and to the use thereof for an active matrix display based on the ECB or IPS effect.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: September 14, 2004
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Eike Poetsch, Volker Reiffenrath
  • Preservatives for vaccines
    Patent number: 6790445
    Abstract: Novel combination of preservatives (methyl and propyl parabens, benzyl alcohol, and 2-phenoxyethanol) were found to pass antimicrobial testing according to USP, BP, and EP. The new preservatives were put into vaccines using L-histidine as a buffer to keep pH at 7.0. HPLC methods were developed to analyze these preservatives and their degradation products.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: September 14, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Assunta S. Ng, Ralph J. Mancinelli, John P. Hennessey
  • Solid oral dosage form comprising a combination of metformin and glibenclamide
    Patent number: RE38629
    Abstract: The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: October 19, 2004
    Assignee: Merck Sante
    Inventors: Yves Bonhomme, Geoffrey Nicholson, Gillian Cave, Sarah J. Nicholson